The average of price targets set by Wall Street analysts indicates a potential upside of 84.5% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable, ...

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...

Equities research analysts at Leerink Partnrs boosted their FY2024 earnings estimates for Beam Therapeutics in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M ...

Beam Therapeutics (BEAM – Research Report) received a Buy rating and a $37.00 price target from Bernstein analyst William Pickering today. The ...

Beam Therapeutics (BEAM) announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease in ...

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has earned an average rating of “Moderate Buy” from the twelve ...

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

Beam Therapeutics is set to present positive and significant data from the BEACON Phase 1/2 clinical trial of BEAM-101 at a major conference, enhancing visibility and credibility within the ...

Check the time stamp on this data. Updated AI-Generated Signals for Beam Therapeutics Inc. (BEAM) available here: BEAM. Type ...

CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...